- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Patent holdings for IPC class A61P 3/10
Total number of patents in this class: 13025
10-year publication summary
|
341
|
331
|
545
|
767
|
725
|
843
|
841
|
806
|
819
|
675
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Eli Lilly and Company | 3880 |
184 |
| Boehringer Ingelheim International GmbH | 4649 |
162 |
| Novo Nordisk A/S | 2273 |
122 |
| Takeda Pharmaceutical Company Limited | 2713 |
116 |
| Janssen Pharmaceutica N.V. | 3352 |
113 |
| F. Hoffmann-La Roche AG | 7944 |
111 |
| Daiichi Sankyo Company, Limited | 1881 |
92 |
| Pfizer Inc. | 3388 |
85 |
| Sanofi | 4115 |
80 |
| The Regents of the University of California | 20211 |
78 |
| Shionogi & Co., Ltd. | 840 |
76 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 839 |
74 |
| Novartis AG | 10674 |
71 |
| Société des Produits Nestlé S.A. | 9858 |
66 |
| Merck Sharp & Dohme LLC | 3739 |
65 |
| Sunshine Lake Pharma Co., Ltd. | 600 |
62 |
| Sanofi-Aventis Deutschland GmbH | 2612 |
53 |
| Bristol-myers Squibb Company | 4847 |
51 |
| Merck Sharp & Dohme Corp. | 2189 |
50 |
| The Board of Trustees of the Leland Stanford Junior University | 6507 |
49 |
| Other owners | 11265 |